Allogene Therapeutics Inc. (NASDAQ:ALLO) went down by -13.45% from its latest closing price compared to the recent 1-year high of $39.12. The company’s stock price has collected -9.79% of loss in the last five trading sessions. Press Release reported 2 hours ago that Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T(TM) Clinical Trials
Is It Worth Investing in Allogene Therapeutics Inc. (NASDAQ :ALLO) Right Now?
Opinions of the stock are interesting as 13 analysts out of 18 who provided ratings for Allogene Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $32.31, which is $20.97 above the current price. ALLO currently public float of 74.43M and currently shorts hold a 7.56% ratio of that float. Today, the average trading volume of ALLO was 2.15M shares.
ALLO’s Market Performance
ALLO stocks went down by -9.79% for the week, with a monthly drop of -28.82% and a quarterly performance of 2.51%, while its annual performance rate touched -51.70%. The volatility ratio for the week stands at 6.25% while the volatility levels for the past 30 days are set at 7.13% for Allogene Therapeutics Inc.. The simple moving average for the period of the last 20 days is -22.79% for ALLO stocks with a simple moving average of -49.91% for the last 200 days.
Analysts’ Opinion of ALLO
Stifel, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $18, previously predicting the price at $44. The rating they have provided for ALLO stocks is “Hold” according to the report published on October 08th, 2021.
Goldman gave a rating of “Neutral” to ALLO, setting the target price at $20 in the report published on October 08th of the previous year.
ALLO Trading at -32.43% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.22% of loss for the given period.
Volatility was left at 7.13%, however, over the last 30 days, the volatility rate increased by 6.25%, as shares sank -33.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.25% lower at present.
During the last 5 trading sessions, ALLO fell by -21.76%, which changed the moving average for the period of 200-days by -64.59% in comparison to the 20-day moving average, which settled at $14.79. In addition, Allogene Therapeutics Inc. saw -9.79% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ALLO starting from Amado Rafael, who sale 11,507 shares at the price of $24.35 back on Oct 01. After this action, Amado Rafael now owns 323,928 shares of Allogene Therapeutics Inc., valued at $280,185 using the latest closing price.
Bhavnagri Veer, the General Counsel of Allogene Therapeutics Inc., sale 5,000 shares at $24.77 during a trade that took place back on Sep 15, which means that Bhavnagri Veer is holding 421,669 shares at $123,844 based on the most recent closing price.
Stock Fundamentals for ALLO
The total capital return value is set at -28.48, while invested capital returns managed to touch -27.64. Equity return is now at value -24.20, with -21.70 for asset returns.
Based on Allogene Therapeutics Inc. (ALLO), the company’s capital structure generated 4.98 points at debt to equity in total, while total debt to capital is 4.75. Total debt to assets is 4.38, with long-term debt to equity ratio resting at 4.71. Finally, the long-term debt to capital ratio is 4.48.
When we switch over and look at the enterprise to sales, we see a ratio of 29.77, with the company’s debt to enterprise value settled at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.96.